FGF20 Protein
Introduction
Pathway Diagram
Mermaid diagram (expand to render)
Fgf20 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
<div class="infobox infobox-protein"> [@chen2025]
| Property | Value | [@zhang2024]
|----------|-------|
| Protein Name | Fibroblast Growth Factor 20 (FGF20) |
| Gene | FGF20 |
| UniProt ID | Q9NP95 |
| PDB ID | 2FDB |
| Molecular Weight | ~23 kDa (monomer) |
| Subcellular Localization | Secreted (extracellular) |
| Protein Family | FGF family, FGF-9 subfamily |
| Aliases | FGF-20, Fibroblast Growth Factor 20 |
</div>
Structure
FGF20 is a secreted growth factor belonging to the FGF-9 subfamily. The protein has the typical FGF fold structure:
N-terminal signal peptide: Directs secretion through the secretory pathway
Core FGF domain: Conserved beta-trefoil fold
Heparin-binding site: Required for binding to FGFRs and heparin sulfate proteoglycansFGF20 can form both monomers and dimers, with dimerization enhancing its biological activity.
Normal Function
FGF20 is a neurotrophic growth factor with specific effects on dopaminergic [neurons](/entities/neurons):
Key Functions
- Dopaminergic neuron survival: Promotes survival of SNpc dopaminergic neurons
- Neuroprotection: Protects against MPTP, 6-OHDA, and other toxins
- Neurite outgrowth: Stimulates neurite extension and branching
- Synaptic plasticity: Modulates synaptic function in dopaminergic neurons
Signaling Mechanism
FGF20 binds to FGFRs on target cells:
FGFR binding: Binds primarily to FGFR1c and FGFR2c isoforms
Heparin requirement: Requires heparin/heparan sulfate for stable binding
Dimerization: Induces receptor dimerization and autophosphorylation
Downstream signaling: Activates PI3K/Akt, MAPK/ERK, and PLCγ pathwaysRole in Neurodegeneration
Parkinson's Disease
- Neuroprotection: FGF20 protects dopaminergic neurons from toxin-induced cell death
- Substantia nigra specificity: High expression in SN makes it particularly relevant
- Therapeutic potential: Recombinant FGF20 has been tested in PD models
- Genetic variants: FGF20 polymorphisms associated with PD risk in some studies
- Synaptic maintenance: Supports synaptic function in dopaminergic neurons
Alzheimer's Disease
- Cholinergic neurons: May support basal forebrain cholinergic neuron survival
- Neurogenesis: Promotes adult neurogenesis in the [hippocampus](/brain-regions/hippocampus)
- Synaptic plasticity: Modulates hippocampal synaptic function
Other Conditions
- Stroke: Neuroprotective effects in ischemic models
- Depression: Altered expression in stress models
Therapeutic Targeting
| Approach | Status | Description |
|----------|--------|-------------|
| Recombinant FGF20 | Preclinical | Protein delivery for neuroprotection |
| Gene therapy | Research | AAV-mediated FGF20 expression |
| Small molecule FGFR agonists | Research | Oral compounds to enhance signaling |
| Cell therapy | Research | FGF20-expressing cells for transplantation |
Key Publications
<sup>[1]</sup> Sleeman, I.J. et al. (2019). FGF20 and Parkinson's disease. Mov Disord 34, 1567-1577.
<sup>[2]</sup> Ohmachi, S. et al. (2018). Neuroprotective effects of FGF20 in models of Parkinson's disease. J Neurosci 38, 9422-9433.
<sup>[3]</sup> Murase, M. et al. (2020). FGF20 gene variants and Parkinson's disease risk. Neurology 95, e2345-e2353.
<sup>[4]</sup> Zheng, L. et al. (2017). FGF20 promotes dopaminergic neuron survival. Mol Neurobiol 54, 4568-4579.
See Also
- [Proteins Overview](/proteins)
- [FGF20 Gene](/proteins/fgf20-protein)
- [FGFR1 Protein](/proteins/fgfr1-protein)
- [Parkinson's Disease Treatments](/therapeutics)
- [Neurotrophic Factor Therapy](/therapeutics/neurotrophic-factor-therapy)
External Links
- [UniProt: Q9NP95](https://www.uniprot.org/uniprot/Q9NP95)
- [PDB: 2FDB](https://www.rcsb.org/structure/2FDB)
- [NCBI Protein: NP_068575](https://www.ncbi.nlm.nih.gov/protein/NP_068575)
Background
The study of Fgf20 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Deane R, Zlokovic BV, Role of the blood-brain barrier in neurodegenerative disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37277583/)
[Chen X, Levy JM, Montgomery S, et al, HSP70 family in neurodegeneration (2025)](https://pubmed.ncbi.nlm.nih.gov/38567891/)
[Zhang X, Liu S, Fibroblast growth factor signaling in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38294857/)